Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on SHR1459 PK in Healthy Subjects
NCT04455100Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of edralbrutinib in B cell malignancies and primary membranous nephropathy (PMN), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration of SHR1459 at Day 9 and Area Under the Concentration-Time Curve of SHR1459 at Day 9. Started Jul 2020; status: completed.
02
Drugs
edralbrutinib
03
Conditions
B cell malignanciesprimary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT04455100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04455100.